Stem-Cell Transplantation
Rituximab active against refractory chronic GVHD
Published in Blood Weekly, October 30th, 2003
In a recent study, scientists in the United States "reviewed the clinical outcome of eight patients with steroid-refractory chronic graft-versus-host disease (GVHD) who received an anti-CD20 chimeric monoclonal antibody (rituximab)."
"Rituximab was given by intravenous infusion at a weekly dose of 375 mg/m2 for 4 weeks," noted V. Ratanatharathorn and coauthors at the University of Michigan Cancer Center. "All patients had received extensive treatment with various immunosuppressive agents; six patients had also received...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2003-10-30)
More Articles from Blood Weekly
- Stem-Cell Transplantation
Costimulation blockade induces hematopoietic chimerism, central tolerance in SCT patients - Myeloma Therapy
Treosulfan shows promise for multiple myeloma treatment - Stem-Cell Research
A58 oncogene can immortalize hematopoietic cells - Stem-Cell Research
Hematopoietic and mature blood cells can differentiate into cardiomyocytes - Transfusion Medicine
Dipyridamole improves efficacy of plasma exchange in TTP patients - Anthrax
$3.5M grant from U.S. government used for drug to treat anthrax exposure - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
